<p>Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - 获取免费报告) 的股价在周二的午盘交易中达到了新的 52 周高点。该股最高交易价格为 36.13 美元，最后交易价格为 35.83 美元，成交量为 3,355,702 股。该股此前收盘价为 33.05 美元。</p>
<p>获取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>多家股票研究分析师最近对 OLMA 股票发表了评论。瑞银集团在 10 月 20 日的研究报告中重申了对 Olema Pharmaceuticals 股票的 “买入” 评级。高盛集团将 Olema Pharmaceuticals 的目标价格从 26.00 美元上调至 38.00 美元，并在 12 月 11 日的报告中给予该公司 “买入” 评级。HC Wainwright 将 Olema Pharmaceuticals 的目标价格从 36.00 美元上调至 45.00 美元，并在 12 月 11 日的报告中给予该股 “买入” 评级。古根海姆在 10 月 8 日的研究报告中开始覆盖 Olema Pharmaceuticals。他们对该公司发布了 “买入” 评级和 20.00 美元的价格目标。最后，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Olema Pharmaceuticals 股票的 “卖出（d-）” 评级。七位分析师对该股给予了买入评级，一位给予了持有评级，一位对该公司的股票发布了卖出评级。根据 MarketBeat.com 的数据，该股的共识评级为 “适度买入”，共识目标价格为 40.50 美元。</p>
<p><strong>阅读我们关于 OLMA 的最新报告</strong></p>
<h2>Olema Pharmaceuticals 股票表现</h2>
<p>该公司的债务与股本比率为 0.01，流动比率为 8.03，速动比率为 8.03。该公司的 50 日移动平均价格为 16.23 美元，200 日移动平均价格为 9.47 美元。该公司的市值为 24.6 亿美元，市盈率为-19.16，贝塔值为 1.87。</p>
<p>Olema Pharmaceuticals (NASDAQ:OLMA - 获取免费报告) 最近在 11 月 10 日发布了季度财报。该公司报告每股收益（EPS）为-0.49 美元，低于分析师的共识预期-0.44 美元，差距为 0.05 美元。平均而言，股票研究分析师预测 Olema Pharmaceuticals, Inc.在本年度将发布-2.33 的每股收益。</p>
<h2>内部活动</h2>
<p>在相关消息中，董事 Cyrus Harmon 在 9 月 18 日的交易中出售了 10,000 股该股票。该股票以平均价格 8.33 美元出售，总交易额为 83,300.00 美元。出售完成后，该董事直接持有 744,140 股公司股票，估值约为 6,198,686.20 美元。此交易代表其持股比例减少了 1.33%。该出售在与 SEC 的法律文件中披露，可以通过此链接访问。目前，16.36% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>多家机构投资者最近买入和卖出了 OLMA 股票。Ameritas Investment Partners Inc.在第二季度将其在 Olema Pharmaceuticals 的持股增加了 55.4%。Ameritas Investment Partners Inc.现在拥有 6,080 股公司股票，价值 26,000 美元，此前在上个季度购买了 2,168 股。Farther Finance Advisors LLC 在第二季度将其在 Olema Pharmaceuticals 的持股增加了 602.9%。Farther Finance Advisors LLC 现在拥有 6,839 股公司股票，价值 29,000 美元，此前在上个季度购买了 5,866 股。FNY Investment Advisers LLC 在第二季度将其在 Olema Pharmaceuticals 的持股增加了 100.0%。FNY Investment Advisers LLC 现在拥有 10,000 股公司股票，价值 42,000 美元，此前在上个季度购买了 5,000 股。Quarry LP 在第一季度购买了 Olema Pharmaceuticals 的新股份，价值约为 45,000 美元。最后，Alpine Global Management LLC 在第一季度购买了 Olema Pharmaceuticals 的新职位，价值约为 52,000 美元。机构投资者持有该公司 91.78% 的股票。</p>
<h2>Olema Pharmaceuticals 公司简介</h2>
<p>(获取免费报告)</p>
<p>Olema Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于女性癌症治疗的发现、开发和商业化。其主要产品候选药物为 OP-1250，一种雌激素受体（ER）拮抗剂和选择性 ER 降解剂，目前正在进行针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的三期临床试验；以及 OP-1250 与 CDK4/6 抑制剂 palbociclib、ribociclib 和 alpelisib 联合进行的针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的 1/2 期临床试验，同时开发 OPERA-01 用于 ER+/HER2-晚期或转移性乳腺癌的治疗。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票超过 Olema Pharmaceuticals</li>
<li>如何投资小型股</li>
<li>ServiceNow 的 70 亿美元赌注：恐慌还是机会？</li>
<li>现在购买的 3 只沃伦·巴菲特股票</li>
<li>戴尔和惠普正在涨价——投资者应注意</li>
<li>WallStreetBets 是什么，它们正在关注哪些股票？</li>
<li>为什么 DLocal 是 2026 年值得关注的顶级新兴市场金融科技股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Olema Pharmaceuticals 吗？</h2>
<p>在你考虑 Olema Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Olema Pharmaceuticals 并不在名单上。</p>
<p>虽然 Olema Pharmaceuticals 目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OLMA

<p>Olema Pharmaceuticals（纳斯达克代码：OLMA）达到了新的 52 周高点，交易价格为 36.13 美元，成交量为 3,355,702 股。分析师们给出了混合评级，普遍共识为 “适度买入”，目标价格为 40.50 美元。该公司报告了第三季度每股亏损 0.49 美元。内部人士活动包括董事 Cyrus Harmon 的出售。机构投资者持有 91.78% 的股份。Olema 专注于女性癌症的治疗，其主要产品 OP-1250 正在进行第三阶段临床试验</p>

<p>Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $36.13 and last traded at $35.83, with a volume of 3355702 shares traded. The stock had previously closed at $33.05.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - 获取免费报告) 的股价在周二的午盘交易中达到了新的 52 周高点。该股最高交易价格为 36.13 美元，最后交易价格为 35.83 美元，成交量为 3,355,702 股。该股此前收盘价为 33.05 美元。</p>
</div><p>Get <strong>Olema Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of equities research analysts have recently commented on OLMA shares. UBS Group reaffirmed a &#34;buy&#34; rating on shares of Olema Pharmaceuticals in a research note on Monday, October 20th. The Goldman Sachs Group boosted their target price on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, December 11th. HC Wainwright increased their price target on Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, December 11th. Guggenheim initiated coverage on Olema Pharmaceuticals in a research report on Wednesday, October 8th. They issued a &#34;buy&#34; rating and a $20.00 price objective for the company. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Olema Pharmaceuticals in a research note on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $40.50.</p>
<div class="lb-trans"><p>多家股票研究分析师最近对 OLMA 股票发表了评论。瑞银集团在 10 月 20 日的研究报告中重申了对 Olema Pharmaceuticals 股票的 “买入” 评级。高盛集团将 Olema Pharmaceuticals 的目标价格从 26.00 美元上调至 38.00 美元，并在 12 月 11 日的报告中给予该公司 “买入” 评级。HC Wainwright 将 Olema Pharmaceuticals 的目标价格从 36.00 美元上调至 45.00 美元，并在 12 月 11 日的报告中给予该股 “买入” 评级。古根海姆在 10 月 8 日的研究报告中开始覆盖 Olema Pharmaceuticals。他们对该公司发布了 “买入” 评级和 20.00 美元的价格目标。最后，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Olema Pharmaceuticals 股票的 “卖出（d-）” 评级。七位分析师对该股给予了买入评级，一位给予了持有评级，一位对该公司的股票发布了卖出评级。根据 MarketBeat.com 的数据，该股的共识评级为 “适度买入”，共识目标价格为 40.50 美元。</p>
</div><p><strong>Read Our Latest Report on OLMA</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 OLMA 的最新报告</strong></p>
</div><h2>Olema Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 股票表现</h2>
</div><p>The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. The company's fifty day moving average price is $16.23 and its 200 day moving average price is $9.47. The company has a market cap of $2.46 billion, a PE ratio of -19.16 and a beta of 1.87.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 0.01，流动比率为 8.03，速动比率为 8.03。该公司的 50 日移动平均价格为 16.23 美元，200 日移动平均价格为 9.47 美元。该公司的市值为 24.6 亿美元，市盈率为-19.16，贝塔值为 1.87。</p>
</div><p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.05). On average, equities research analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals (NASDAQ:OLMA - 获取免费报告) 最近在 11 月 10 日发布了季度财报。该公司报告每股收益（EPS）为-0.49 美元，低于分析师的共识预期-0.44 美元，差距为 0.05 美元。平均而言，股票研究分析师预测 Olema Pharmaceuticals, Inc.在本年度将发布-2.33 的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, Director Cyrus Harmon sold 10,000 shares of the stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $8.33, for a total transaction of $83,300.00. Following the completion of the sale, the director directly owned 744,140 shares of the company's stock, valued at approximately $6,198,686.20. This trade represents a 1.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 16.36% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Cyrus Harmon 在 9 月 18 日的交易中出售了 10,000 股该股票。该股票以平均价格 8.33 美元出售，总交易额为 83,300.00 美元。出售完成后，该董事直接持有 744,140 股公司股票，估值约为 6,198,686.20 美元。此交易代表其持股比例减少了 1.33%。该出售在与 SEC 的法律文件中披露，可以通过此链接访问。目前，16.36% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors have recently bought and sold shares of OLMA. Ameritas Investment Partners Inc. increased its position in shares of Olema Pharmaceuticals by 55.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company's stock valued at $26,000 after purchasing an additional 2,168 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Olema Pharmaceuticals by 602.9% during the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company's stock worth $29,000 after buying an additional 5,866 shares during the last quarter. FNY Investment Advisers LLC increased its holdings in Olema Pharmaceuticals by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company's stock worth $42,000 after buying an additional 5,000 shares during the last quarter. Quarry LP bought a new stake in Olema Pharmaceuticals in the first quarter worth about $45,000. Finally, Alpine Global Management LLC purchased a new position in Olema Pharmaceuticals in the first quarter valued at about $52,000. Institutional investors own 91.78% of the company's stock.</p>
<div class="lb-trans"><p>多家机构投资者最近买入和卖出了 OLMA 股票。Ameritas Investment Partners Inc.在第二季度将其在 Olema Pharmaceuticals 的持股增加了 55.4%。Ameritas Investment Partners Inc.现在拥有 6,080 股公司股票，价值 26,000 美元，此前在上个季度购买了 2,168 股。Farther Finance Advisors LLC 在第二季度将其在 Olema Pharmaceuticals 的持股增加了 602.9%。Farther Finance Advisors LLC 现在拥有 6,839 股公司股票，价值 29,000 美元，此前在上个季度购买了 5,866 股。FNY Investment Advisers LLC 在第二季度将其在 Olema Pharmaceuticals 的持股增加了 100.0%。FNY Investment Advisers LLC 现在拥有 10,000 股公司股票，价值 42,000 美元，此前在上个季度购买了 5,000 股。Quarry LP 在第一季度购买了 Olema Pharmaceuticals 的新股份，价值约为 45,000 美元。最后，Alpine Global Management LLC 在第一季度购买了 Olema Pharmaceuticals 的新职位，价值约为 52,000 美元。机构投资者持有该公司 91.78% 的股票。</p>
</div><h2>Olema Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于女性癌症治疗的发现、开发和商业化。其主要产品候选药物为 OP-1250，一种雌激素受体（ER）拮抗剂和选择性 ER 降解剂，目前正在进行针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的三期临床试验；以及 OP-1250 与 CDK4/6 抑制剂 palbociclib、ribociclib 和 alpelisib 联合进行的针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的 1/2 期临床试验，同时开发 OPERA-01 用于 ER+/HER2-晚期或转移性乳腺癌的治疗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Olema Pharmaceuticals</li>
<li>How to Invest in Small Cap Stocks</li>
<li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Dell and HP Are Raising Prices—And Investors Should Take Note</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Olema Pharmaceuticals</li>
<li>如何投资小型股</li>
<li>ServiceNow 的 70 亿美元赌注：恐慌还是机会？</li>
<li>现在购买的 3 只沃伦·巴菲特股票</li>
<li>戴尔和惠普正在涨价——投资者应注意</li>
<li>WallStreetBets 是什么，它们正在关注哪些股票？</li>
<li>为什么 DLocal 是 2026 年值得关注的顶级新兴市场金融科技股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Olema Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Olema Pharmaceuticals 吗？</h2>
</div><p>Before you consider Olema Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Olema Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Olema Pharmaceuticals 并不在名单上。</p>
</div><p>While Olema Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Olema Pharmaceuticals 目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Olema Pharmaceuticals（NASDAQ:OLMA）创下 12 个月新高 - 现在是买入的好时机吗？